Background: The epithelial lining of the gut expresses intestinal fatty-acid binding proteins (I-FABPs), which increase in circulation and in plasma concentration during intestinal damage. From the perspective of obesity, the consumption of a diet rich in fat causes a disruption in the integrity of the gut barrier and an increase in its permeability.
Hypothesis: There is an association between the expression of I-FABP in the gut and various metabolic changes induced by a high-fat (HF) diet.
Methods: Wistar albino rats (n = 90) were divided into three groups (n = 30 per group), viz. One control and two HF diet groups (15 and 30%, respectively) were maintained for 6 weeks. Blood samples were thus collected to evaluate the lipid profile, blood glucose level and other biochemical tests. Tissue sampling was conducted to perform fat staining and immunohistochemistry.
Results: HF diet-fed rats developed adiposity, insulin resistance, leptin resistance, dyslipidemia, and increased expression of I-FABP in the small intestine compared to the control group. Increased I-FABP expression in the ileal region of the intestine is correlated significantly with higher fat contents in the diet, indicating that higher I-FABP expression occurs due to increased demand of enterocytes to transport lipids, leading to metabolic alterations.
Conclusion: In summary, there is an association between the expression of I-FABP and HF diet-induced metabolic alterations, indicating that I-FABP can be used as a biomarker for intestinal barrier dysfunction.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223920 | PMC |
| http://dx.doi.org/10.1186/s12944-023-01837-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of the protective role of resveratrol on LPS-induced septic intestinal barrier function via TLR4/MyD88/NF-κB signaling pathways.
Sci Rep
January 2025
Department of Critical Care Medicine, Tongde Hospital of Zhejiang Province, #234 Gucui Road, Hangzhou, 310012, Zhejiang, People's Republic of China.
The intestinal barrier function is a critical defense mechanism in the human body, serving as both the primary target and initiating organ in cases of sepsis. Preserving the integrity of this barrier is essential for preventing complications and diseases, including sepsis and mortality. Despite this importance, the impact of resveratrol on intestinal barrier function remains unclear.
View Article and Find Full Text PDFInsight of Intestinal Fatty Acid Binding Protein as a Potential Biomarker in the Biology of Epithelial Damage of Gastrointestinal Membrane.
Curr Protein Pept Sci
January 2025
Department of Biotechnology, Motilal Nehru National Institute of Technology Allahabad (MNNITA), Allahabad, India.
The diagnosis of intestinal injury remains a challenge as it is rare in occurrence and transpires in multiple traumatized patients. The deferred finding of injury of intestines upsurges multiple risks such as septicemia, numerous organ failures as well as mortality. In this review, we corroborate with the goals of proposing surrogate biomarkers that consent to the measurement of the permeability of intestines more effortlessly.
View Article and Find Full Text PDFThe efficacy and active compounds of Chaihuang Qingyi Huoxue granule to Ameliorate intestinal mucosal barrier injury in rats with severe acute pancreatitis by suppressing the HMGB1/TLR4/NF-κB signaling pathway.
Int Immunopharmacol
January 2025
Research Center of Integrated Chinese and Western Medicine, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University Luzhou, 646000, China; School of Integrated Traditional Chinese and Western Clinical Medicine, North Sichuan Medical College, Nanchong, 637000, China; College of Integrated Chinese and Western Medicine and the Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, 646000, China; The Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Treatment of Digestive System Diseases of Luzhou city, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Lu zhou, 646000, China. Electronic address:
Intestinal mucosal barrier injury represents a critical complication of severe acute pancreatitis (SAP) without effective treatment. This study investigated the efficacy, underlying mechanism, and responsible active compounds of the traditional Chinese medicinal prescription Chaihuang Qingyi Huoxue granule (CHQY) in treating SAP-induced intestinal mucosal barrier injury. SAP was established in Sprague-Dawley rats via intra-pancreaticobiliary duct infusion of sodium taurocholate, followed by oral CHQY administration (3.
View Article and Find Full Text PDFIntestinal fatty acid binding protein is associated with coronary artery disease in long-term type 1 diabetes-the Dialong study.
Cardiovasc Diabetol
November 2024
Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway.
Article Synopsis
- Individuals with long-term type 1 diabetes may have an increased risk of heart issues due to inflammation caused by gut microbiota entering the bloodstream, leading to atherosclerosis.
- A study involving 102 people with type 1 diabetes and 63 controls measured several biomarkers related to gut inflammation and assessed coronary atherosclerosis using advanced imaging techniques.
- The results indicated that higher levels of intestinal fatty acid binding protein (I-FABP) were linked to significant coronary artery blockages, suggesting it could be a potential marker for heart disease in diabetes patients.
Serum markers of microbial translocation and intestinal damage in assessment of gastrointestinal tract involvement in systemic sclerosis.
Clin Exp Med
September 2024
Department of Translational and Precision Medicine, Sapienza University of Rome, Viale dell'Università 37, 00185, Rome, Italy.
Gastrointestinal (GI) tract involvement affects up to 90% of Systemic sclerosis (SSc) patients. The presence of GI symptoms is assessed by the University of California, Los Angeles, and Scleroderma Clinical Trials Consortium Gastrointestinal Scale (UCLA SCTC GIT 2.0).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!